These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28744159)

  • 41. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients.
    Buda G; Orciuolo E; Carulli G; Galimberti S; Ghio F; Cervetti G; Pelosini M; Petrini M
    Acta Haematol; 2013; 129(1):35-9. PubMed ID: 23107867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.
    Kuhr K; Wirth D; Srivastava K; Lehmacher W; Hellmich M
    Eur J Clin Pharmacol; 2016 Mar; 72(3):257-65. PubMed ID: 26671239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of Daratumumab-Based Regimens Compared to Standard of Care in Transplant-Eligible Multiple Myeloma: A Meta-Analysis.
    Menon T; Kataria S; Adhikari R; Khan H; Khalid MZ; Saeeduddin MO; Taj S; Rehman U; Tekin A; Singh R
    Cureus; 2021 May; 13(5):e15098. PubMed ID: 34155463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
    Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
    PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.
    Mushtaq A; Iftikhar A; Hassan H; Lakhani M; Sagar F; Kamal A; Zahid U; Ali Z; Razzaq F; Zar MA; Hassan SF; Safdar A; Raychaudhuri S; Anwer F
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):447-461. PubMed ID: 31060991
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.
    Wu S; Zheng C; Chen S; Cai X; Shi Y; Lin B; Chen Y
    Biomed Res Int; 2015; 2015():927105. PubMed ID: 26425561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents.
    Su B; Zhu X; Jiang Y; Wang L; Zhao N; Ran X; Zheng X; Guo H
    Leuk Lymphoma; 2019 Jun; 60(6):1381-1388. PubMed ID: 30516074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
    Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.
    Tuchman SA; Moore JO; DeCastro CD; Li Z; Sellars E; Kang Y; Long G; Gasparetto CG
    J Geriatr Oncol; 2017 May; 8(3):165-169. PubMed ID: 28256432
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
    Niesvizky R; Flinn IW; Rifkin R; Gabrail N; Charu V; Clowney B; Essell J; Gaffar Y; Warr T; Neuwirth R; Zhu Y; Elliott J; Esseltine DL; Niculescu L; Reeves J
    J Clin Oncol; 2015 Nov; 33(33):3921-9. PubMed ID: 26056177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
    Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis.
    Wang X; Li Y; Yan X
    Biomed Res Int; 2016; 2016():6848902. PubMed ID: 26949704
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.
    Botta C; Ciliberto D; Rossi M; Staropoli N; Cucè M; Galeano T; Tagliaferri P; Tassone P
    Blood Adv; 2017 Feb; 1(7):455-466. PubMed ID: 29296961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
    Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
    J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer.
    Zhang D; Wu JR; Duan XJ; Wang KH; Zhao Y; Ni MW; Liu SY; Zhang XM; Zhang B
    Front Pharmacol; 2019; 10():717. PubMed ID: 31333452
    [No Abstract]   [Full Text] [Related]  

  • 58. Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data.
    Chan H; Chai K; Shih S; Lewsey R; Chen K; McDiarmid B; Jackson S; Simpson D
    Br J Haematol; 2019 Nov; 187(4):470-477. PubMed ID: 31298750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
    McCarthy PL; Holstein SA; Petrucci MT; Richardson PG; Hulin C; Tosi P; Bringhen S; Musto P; Anderson KC; Caillot D; Gay F; Moreau P; Marit G; Jung SH; Yu Z; Winograd B; Knight RD; Palumbo A; Attal M
    J Clin Oncol; 2017 Oct; 35(29):3279-3289. PubMed ID: 28742454
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary Plasma Cell Leukemia: Identity Card 2016.
    Musto P; Simeon V; Todoerti K; Neri A
    Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.